Zanubrutinib Approved in Waldenstrom Macroglobulinemia and MZL

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：649 / 649
页数：1
相关论文
共 50 条
  • [1] Zanubrutinib for the treatment of Waldenstrom Macroglobulinemia
    Lim, Kenneth J. C.
    Tam, Constantine S.
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (12) : 1303 - 1310
  • [2] Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia
    Sarosiek, Shayna
    Sermer, David
    Branagan, Andrew R.
    Treon, Steven P.
    Castillo, Jorge J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) : 471 - 478
  • [3] Zanubrutinib Shows Clinical Benefits in Waldenstrom Macroglobulinemia
    不详
    ONCOLOGIST, 2020, 25 : S16 - S17
  • [4] Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenstrom Macroglobulinemia
    Munoz, Javier
    Paludo, Jonas
    Sarosiek, Shayna
    Castillo, Jorge J.
    CELLS, 2022, 11 (20)
  • [5] THE BUDGET IMPACT OF ZANUBRUTINIB FOR THE TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Campbell, D.
    Zimmerman, T.
    Migliaccio-Walle, K.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (07) : S430 - S431
  • [6] A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenstrom's macroglobulinemia
    Patel, Dave
    Sidana, Megan
    Mdluli, Xolani
    Patel, Vallari
    Stapleton, Ann
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1917 - 1921
  • [7] Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
    Trotman, Judith
    Opat, Stephen
    Gottlieb, David
    Simpson, David
    Marlton, Paula
    Cull, Gavin
    Munoz, Javier
    Tedeschi, Alessandra
    Roberts, Andrew W.
    Seymour, John F.
    Atwal, Siminder Kaur
    Yu, Yiling
    Novotny, William
    Holmgren, Eric
    Tan, Ziwen
    Hilger, James D.
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2020, 136 (18) : 2027 - 2037
  • [8] Real-world data of zanubrutinib treatment for patients with previously treated Waldenstrom Macroglobulinemia
    Jang, Seo Yoon
    Kwon, Soyean
    Byun, Ja Min
    Koh, Youngil
    Hong, Junshik
    Yoon, Sung-Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S277 - S277
  • [9] Imbruvica Approved for Third Indication, Waldenstrom's Macroglobulinemia, as Breakthrough Therapy
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (06): : 41 - 44
  • [10] A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
    Tam, Constantine S.
    Opat, Stephen
    D'Sa, Shirley
    Jurczak, Wojciech
    Lee, Hui-Peng
    Cull, Gavin
    Owen, Roger G.
    Marlton, Paula
    Wahlin, Bjorn E.
    Garcia Sanz, Ramon
    McCarthy, Helen
    Mulligan, Stephen
    Tedeschi, Alessandra
    Castillo, Jorge J.
    Czyz, Jaroslaw
    Fernandez de Larrea, Carlos
    Belada, David
    Libby, Edward
    Matous, Jeffrey, V
    Motta, Marina
    Siddiqi, Tanya
    Tani, Monica
    Trneny, Marek
    Minnema, Monique C.
    Buske, Christian
    Leblond, Veronique
    Trotman, Judith
    Chan, Wai Y.
    Schneider, Jingjing
    Ro, Sunhee
    Cohen, Aileen
    Huang, Jane
    Dimopoulos, Meletios
    BLOOD, 2020, 136 (18) : 2038 - 2050
12345